Fig. 1

APP/PS1 pathology and STZ cooperatively promote cytokine expression. a Luminex analysis of 22 cytokines (columns, z-scored) expressed in the cortex of APP/PS1, STZ, and APP/PS1-STZ mice (each row is a cortex sample). b Partial least squares discriminant analysis (PLSDA) identified two profiles of cytokines, LV1 and LV2, that distinguished groups. LV1 separated APP/PS1-STZ mice (positive) from both APP/PS1 and STZ mice (negative). LV2 separated STZ mice (positive) from APP/PS1 mice (negative). c The weighted profile of cytokines representing LV1. Errors bars on each cytokine were computed by PLSDA model regeneration using iterative subsampling of 80% of samples (mean ± SD). d Scoring the data for each sample in a on LV1 revealed that combined APP/PS1-STZ pathology cooperatively increased the LV1 cytokine profile compared to either APP/PS1 or STZ pathology alone (***p < 0.001, Welch’s ANOVA with Dunnett’s T3 test). e The weighted profile of cytokines representing LV2. Errors bars on each cytokine were computed by PLSDA model regeneration using iterative subsampling of 80% of samples (mean ± SD). f Scoring the data for each sample in b on LV2 revealed that STZ is significantly upregulated on the LV2 cytokine profile compared to APP/PS1 (*p < 0.05, Welch’s ANOVA with Dunnett’s T3 test). Data were collected from 21 mice (16 M/12/F, STZ5M/2F, APP/PS1 3 M/4F, APP/PS1-STZ 4 M/3F)